Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC nasal decongestant monograph amended to add levmetamfetamine.

This article was originally published in The Tan Sheet

Executive Summary

OTC NASAL DECONGESTANT MONOGRAPH AMENDED TO ADD LEVMETAMFETAMINE, formerly known as l-desoxyephedrine, as a safe and effective OTC active ingredient, FDA announces in a final rule published in the July 30 Federal Register. L-desoxyephedrine was excluded from the August 1994 final monograph for nasal decongestant drug products because U.S. Pharmacopoeial standards did not exist for the ingredient. USP proposed a monograph for l-desoxyephedrine in the January/February 1997 Pharmacopeial Forum, which included the name change to levmetamfetamine. In affirming levmetamfetamine's GRAS/E (generally recognized as safe/effective) status, the final rule removes l-desoxyephedrine from the list of nonmonograph active ingredients.

You may also be interested in...



Nasal Decongestant Final Rule Six-Month Stay Sought By P&G

A six-month stay of the effective date of FDA's final rule switching the name of the OTC nasal decongestant ingredient l-desoxyephedrine to levmetamfetamine is requested by Procter & Gamble in a Sept. 7 petition.

Nasal Decongestant Final Rule Six-Month Stay Sought By P&G

A six-month stay of the effective date of FDA's final rule switching the name of the OTC nasal decongestant ingredient l-desoxyephedrine to levmetamfetamine is requested by Procter & Gamble in a Sept. 7 petition.

Nasal Decongestant Final Rule Six-Month Stay Sought By P&G

A six-month stay of the effective date of FDA's final rule switching the name of the OTC nasal decongestant ingredient l-desoxyephedrine to levmetamfetamine is requested by Procter & Gamble in a Sept. 7 petition.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS088724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel